Caliway Biopharmaceuticals (TWSE:6919), a Taiwan-based clinical-stage biopharmaceutical company, announced on Thursday that the latest preclinical data on its first-in-class large-area localised fat reduction drug candidate, CBL-514, in combination with GLP-1R-based therapies, has been selected for presentation at the 2026 Scientific Sessions of the American Diabetes Association (ADA).

Caliway's research has also been selected for presentation at both ECO, the European Congress on Obesity, and the ADA's two premier scientific meetings in obesity and metabolism in Europe and the United States. According to Caliway, this highlights the research direction of CBL-514 in combination with GLP-1R-based weight-loss therapies, including its potential complementary value in metabolic parameters, and reflects strong recognition and attention from international experts in metabolism.

The ADA's 2026 Scientific Sessions will be held in June in New Orleans, Louisiana. The presentation will be delivered by W. Timothy Garvey, MD, an authority in obesity and metabolic medicine and a scientific advisor to Caliway. Dr. Garvey is Professor of Endocrinology and Obesity Medicine at the University of Alabama at Birmingham (UAB).

The title of the selected abstract is: 'Combination of Tirzepatide with CBL-514 an Adipocyte-Apoptosis Agent Improves Weight Loss Durability and Adipose Tissue Remodeling in Diet-Induced Obese Rats'.